No Data
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
H.C. Wainwright Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $80
Promising Potential of Structure Therapeutics' ACCG-2671 Drives Buy Rating
Buy Rating for Structure Therapeutics, Inc. Driven by Innovative Drug Development and Promising Obesity Treatment Platform
Express News | Shares of Viking Therapeutics up 4.2%, Amgen up 1%